Advertisement
Screener

MACROGENICS, INC. (MGNX) Deferred Tax Assets, Deferred Income

2.8 / 5 stars · 68/120 Roast Me

MACROGENICS, INC. Deferred Tax Assets, Deferred Income

MACROGENICS, INC. (MGNX) had Deferred Tax Assets, Deferred Income of $35.11 million as of 2025-12-31, per its 10-K filed 2026-03-09.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross

us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2026-03-09

  • 2025-12-31: Deferred Tax Assets, Deferred Income $35.11M.
  • 2024-12-31: Deferred Tax Assets, Deferred Income $18.80M.
  • 2023-12-31: Deferred Tax Assets, Deferred Income $17.44M.
  • 2022-12-31: Deferred Tax Assets, Deferred Income $0.00.
Period endDeferred Tax Assets, Deferred IncomeDeferred Tax Assets, Deferred Income as first filed
2025-12-31$35.11M
10-K · filed 2026-03-09
2024-12-31$18.80M
10-K · filed 2026-03-09
2023-12-31$17.44M
10-K · filed 2025-03-20
2022-12-31$0.00
10-K · filed 2024-03-07
2021-12-31$1.25M
10-K · filed 2023-03-15
2020-12-31$3.13M
10-K · filed 2022-02-24
2019-12-31$367.00K
10-K · filed 2021-02-25
2018-12-31$3.74M
10-K · filed 2020-02-25
2017-12-31$2.98M
10-K · filed 2019-02-26
2016-12-31$5.10M
10-K · filed 2018-02-27
2015-12-31$6.63M
10-K · filed 2017-02-28
2014-12-31$3.99M
10-K · filed 2016-02-29
2013-12-31$8.22M
10-K · filed 2015-03-03
$8.22M
10-K · filed 2014-03-20
2012-12-31$9.38M
10-K · filed 2014-03-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35